Perceptive Advisors reports 8.9% stake in IKT

INHIBIKASE THERAPEUTICS, INC. ownership disclosure: Perceptive Advisors, Joseph Edelman and Perceptive Life Sciences Master Fund report shared beneficial ownership equal to 8.9% of Common Stock.

Rhea-AI Filing Summary

INHIBIKASE THERAPEUTICS, INC. ownership disclosure: Perceptive Advisors, Joseph Edelman and Perceptive Life Sciences Master Fund report shared beneficial ownership equal to 8.9% of Common Stock.

The filing states 12,635,875 shares of shared voting and dispositive power and references 132,032,636 shares outstanding as of May 1, 2026, assuming exercise of Warrants for 10,320,875 shares subject to a 9.99% ownership limitation.

Insights

Institutional Ownership Analyst

Large shared position disclosed at roughly 8.9%.

The filing lists shared voting and dispositive power of 12,635,875 shares for Perceptive Advisors, Joseph Edelman and the Master Fund. It explains that the reported 8.9% percentage is based on 132,032,636 shares outstanding as of May 1, 2026 and assumes exercise of Warrants for 10,320,875 shares.

Key dependency: the Warrants carry a contractual cap—they may not be exercised to exceed 9.99% beneficial ownership. Subsequent filings may disclose exercises or changes in the outstanding share count that alter the percentage.

Securities Counsel (Disclosure)

Disclosure ties beneficial ownership to warrant exercise limits under Section 13(d).

The statement clarifies who holds direct shares and who holds warrants: the Master Fund holds direct shares and various warrants including Pre-Funded Warrants and two series of common warrants. The filing explicitly ties the exercisability of those Warrants to a 9.99% beneficial ownership cap.

Practical point: cash‑flow treatment or timing of any exercise is not stated here; any change in ownership from warrant exercise will require further Section 13D/G or Form 4/5 filings as applicable.

Key Figures

Shares outstanding: 132,032,636 shares Shared voting/dispositive power: 12,635,875 shares Reported ownership percentage: 8.9% +4 more

7 metrics

Shares outstanding 132,032,636 shares as of May 1, 2026

Shared voting/dispositive power 12,635,875 shares reported for Perceptive Advisors, Mr. Edelman, Master Fund

Reported ownership percentage 8.9% calculated based on outstanding shares and assumed warrant exercise

Warrants referenced (aggregate) 10,320,875 shares assumed exercisable under filing's limitation

Direct shares held by Master Fund 2,315,000 shares direct common stock holding disclosed

Pre-Funded Warrants 790,000 shares (pre-funded) exercise price $0.001 per share as disclosed

Common warrants series 3,357,211 and 6,173,664 shares exercise prices $1.37 and $1.49 per share respectively

Key Terms

Pre-Funded Warrants, Section 13(d), beneficially own

3 terms

Pre-Funded Warrants financial

"pre-funded warrants (the "Pre-Funded Warrants") to purchase 790,000 shares"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

Section 13(d) regulatory

"as determined in accordance with Section 13(d) of the Securities Exchange Act"

A Section 13(d) filing is a public disclosure required under U.S. securities law when a person or group acquires more than 5% of a company’s registered equity and may influence control. The filer must report who owns the shares, how they were acquired, and any plans or intentions for the company, so the market and other shareholders can see if a large buyer is attempting a takeover or other strategic move. Think of it like a formal announcement that someone has crossed a threshold and is showing their hand.

beneficially own regulatory

"would beneficially own, as determined in accordance with Section 13(d)"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Perceptive Advisors report in INHIBIKASE (IKT)?

Perceptive Advisors and related reporting persons state shared beneficial ownership of 12,635,875 shares, equal to 8.9% of common stock based on 132,032,636 shares outstanding as of May 1, 2026.

How many shares does the Perceptive Life Sciences Master Fund directly hold in IKT?

The Master Fund directly holds 2,315,000 shares of common stock. The filing also lists other warrant positions that are disclosed separately and not counted as direct shares.

What Warrants are disclosed by the reporting persons in the IKT filing?

The filing lists Pre‑Funded Warrants to purchase 790,000 shares and common warrants to purchase 3,357,211 and 6,173,664 shares, totaling 10,320,875 shares referenced for exercise assumptions.

Does the filing limit warrant exercises for Perceptive and affiliates?

Yes; the Warrants include a provision that they may not be exercised if the Reporting Persons would beneficially own more than 9.99% of outstanding common stock after exercise, per the filing's language.

On what share count is the 8.9% ownership percentage based?

The ownership percentage is calculated using 132,032,636 shares outstanding as of May 1, 2026, as stated in the issuer's Form 10‑Q cited in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 04:00 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

INHIBIKASE THERAPEUTICS, INC.

(Name of Issuer)

Common Stock, $0.001 par value

(Title of Class of Securities)

45719W205

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 45719W205

1

Names of Reporting Persons

Perceptive Advisors LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 12,635,875.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 12,635,875.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

12,635,875.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.9 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP Number(s): 45719W205

1

Names of Reporting Persons

Joseph Edelman

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 12,635,875.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 12,635,875.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

12,635,875.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.9 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP Number(s): 45719W205

1

Names of Reporting Persons

Perceptive Life Sciences Master Fund, Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 12,635,875.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 12,635,875.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

12,635,875.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.9 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: INHIBIKASE THERAPEUTICS, INC.
(b)	Address of issuer's principal executive offices: 1000 N. West Street, Suite 1200, Wilmington, DE, 19801
Item 2.
(a)	Name of person filing: The names of the persons filing this report (collectively, the "Reporting Persons") with respect to shares of Common Stock, par value $0.001 per share (the "Common Stock") of INHIBIKASE THERAPEUTICS, INC. (the "Issuer") are: (i) Perceptive Advisors LLC ("Perceptive Advisors") (ii) Joseph Edelman ("Mr. Edelman") (iii) Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund")
(b)	Address or principal business office or, if none, residence: The address of the principal business office of each of the Reporting Persons is: 51 Astor Place, 10th Floor, New York, NY 10003
(c)	Citizenship: Perceptive Advisors is a Delaware limited liability company. Mr. Edelman is a United States citizen. The Master Fund is a Cayman Islands corporation.
(d)	Title of class of securities: Common Stock, $0.001 par value
(e)	CUSIP No.: 45719W205
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership percentages reported are based on 132,032,636 outstanding shares of Common Stock as of May 1, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026, and assume the exercise of Warrants (as defined below) held by the Reporting Persons for 10,320,875 shares of Common Stock. Neither Perceptive Advisors nor Mr. Edelman directly holds any Common Stock. The Master Fund directly holds (i) 2,315,000 shares of Common Stock, (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase 790,000 shares of Common Stock at an exercise price of $0.001 per share, (iii) common warrants to purchase 3,357,211 shares of Common Stock at an exercise price of $1.37 per share, and (iv) common warrants to purchase 6,173,664 shares of Common Stock at an exercise price of $1.49 per share (together with the Pre-Funded Warrants, the "Warrants"). The terms of the Warrants provide that the Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 9.99% of the shares of Common Stock then issued and outstanding. As of the date hereof, this limitation permits the Reporting Persons to exercise Warrants for up to 10,320,875 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors.
(b)	Percent of class: Perceptive Advisors: 8.9% Mr. Edelman: 8.9% Master Fund: 8.9%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0
	(ii) Shared power to vote or to direct the vote: Perceptive Advisors: 12,635,875 Mr. Edelman: 12,635,875 Master Fund: 12,635,875
	(iii) Sole power to dispose or to direct the disposition of: Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0
	(iv) Shared power to dispose or to direct the disposition of: Perceptive Advisors: 12,635,875 Mr. Edelman: 12,635,875 Master Fund: 12,635,875
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Perceptive Advisors LLC

Signature:	/s/ Joseph Edelman
Name/Title:	Joseph Edelman, Managing Member
Date:	05/15/2026

Joseph Edelman

Signature:	/s/ Joseph Edelman
Name/Title:	Joseph Edelman
Date:	05/15/2026

Perceptive Life Sciences Master Fund, Ltd.

Signature:	/s/ Joseph Edelman
Name/Title:	Joseph Edelman, Managing Member
Date:	05/15/2026